Am J Health-Syst Pharm
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Order Full text via Infotrieve
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McGhan, W.
Right arrow Articles by Smith, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McGhan, W.
Right arrow Articles by Smith, M.
American Journal of Health-System Pharmacy, Vol 53, Issue 1, 45-52
Copyright © 1996 by American Society of Health-System Pharmacists


Articles

Pharmacoeconomic analysis of smoking-cessation interventions

WF McGhan and MD Smith


A model for evaluating the costs and benefits of smoking-cessation interventions is proposed and published data on the subject are analyzed. Decision-tree analysis was used to determine the costs and benefits, from an employer's perspective, of several smoking-cessation options. The probability that a smoker would stop smoking was based on two published meta-analyses of smoking-cessation interventions and a national study of nicotine patch users who received a smoking-cessation consultation from a pharmacist. The costs were determined by telephone interviews and market research information. A sensitivity analysis of treatment costs was conducted to determine the optimal treatment from the standpoint of costs versus benefits. The smoking-cessation intervention from which an employer would receive the greatest net benefit is the nicotine patch with smoking-cessation consultation from a pharmacist and patient participation in a formal smoking-cessation program. Pharmacists included in this analysis could charge a smoking-cessation consultation fee of up to $109 per patient. Pharmacoeconomic analysis suggested that smoking-cessation therapy consisting of treatment with nicotine patches, consultations with pharmacists, and participation in a comprehensive behavioral program would be the most cost-beneficial to employers.
 



This article has been cited by other articles:


Home page
Journal of Pharmacy PracticeHome page
K. S. Hudmon, R. L. Corelli, L. A. Kroon, M. S. Shreve, and A. V. Prokhorov
Reducing Pulmonary Disease: The Pharmacist's Role in Smoking Cessation
Journal of Pharmacy Practice, April 1, 2001; 14(2): 143 - 159.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1996 by the American Society of Health-System Pharmacists.